Record Revenue Growth Fueled by ANKTIVA Adoption
ImmunityBio, Inc. (NASDAQ: IBRX) shares experienced a dramatic surge in recent trading sessions following the company’s announcement of exceptional preliminary financial results for fiscal year 2025. The commercial-stage biotechnology company reported approximately $113 million in preliminary net product revenue, representing a remarkable 700% year-over-year increase. This significant growth was primarily driven by the accelerating adoption of its flagship immunotherapy drug, ANKTIVA. The strong revenue performance, combined with substantial regulatory approvals in international markets and robust quarter-over-quarter growth momentum, has ignited investor enthusiasm and positioned ImmunityBio as a notable success story in the biotechnology sector as it enters 2026.
ImmunityBio delivered extraordinary financial results for 2025, reporting preliminary net product revenue of approximately $113 million for the full year. This figure reflects a remarkable 700% increase compared to 2024. The company’s flagship product, ANKTIVA, which is the first FDA-approved immunotherapy for non-muscle invasive bladder cancer carcinoma in situ, demonstrated exceptional market adoption. Unit sales volume for ANKTIVA grew by an impressive 750% year-over-year.
Revenue in the fourth quarter of 2025 reached approximately $38.3 million, surpassing the third quarter’s revenue of $31.8 million. This marks a 20% sequential increase and a substantial 431% year-over-year jump. President and CEO Richard Adcock attributed this success to the accelerating adoption of ANKTIVA and the continued execution of the company’s commercial strategy. The company maintained a 54% quarter-over-quarter unit volume growth rate throughout fiscal 2025.
IBRX Stock Performance and Analyst Outlook
As of early morning on January 16, 2026, ImmunityBio stock was trading at approximately $3.15 in premarket activity. This represented a slight decrease from the previous session’s dramatic gains. The stock had closed at $3.02 on Wednesday before surging more than 28% on Thursday, January 15. During intraday trading on Thursday, the stock reached highs near $3.99 before settling around $3.91-$3.95.
This performance marked one of the strongest single-day gains for IBRX in recent months. Trading volume reached 58.75 million shares, significantly higher than the average daily volume of 16.44 million shares. Over the past 52 weeks, the stock has traded within a range of $1.83 to $4.27. The recent surge has pushed shares closer to the upper end of this range.
The analyst consensus remains bullish on the stock. Five analysts have recommended buying the stock, with an average 12-month price target of $10.40. This target represents a potential upside of over 200% from current levels. D. Boral Capital has issued the highest analyst target at $24.00, reflecting strong confidence in the company’s commercial trajectory.